key: cord-0883630-6d2rm21e
authors: Lakenman, P.L.M.; van Schie, J. C.; van der Hoven, B.; van Bommel, J.; Olieman, J. F.; Joosten, K.F.M.
title: Nutritional intake and GI symptoms in critically ill covid-19 patients
date: 2021-12-31
journal: Clinical Nutrition ESPEN
DOI: 10.1016/j.clnesp.2021.09.023
sha: 897329c6b22c0ac9d94037d99e4f83e65785744e
doc_id: 883630
cord_uid: 6d2rm21e

nan

Italy; 7 Lecco Hospital, Lecco, Italy; 8 IRCCS of Reggio Emilia, Reggio Emilia, Italy; 9 Humanitas Research Hospital, Rozzano, Italy; 10 ational Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina, Benfratelli, Palermo, Italy; 11 S.Maria delle Croci Hospital, Ravenna, Italy Rationale: To investigate the association between the parameters used in nutritional screening assessment (body mass index [BMI] , unintentional weight loss [WL] and reduced food intake) and clinical outcomes in noncritically ill, hospitalized coronavirus disease 2019 (COVID-19) patients. Methods: This was a prospective multicenter real-life study carried out during the first pandemic wave in 11 Italian Hospitals. In total, 1391 patients were included. The primary end-point was a composite of in-hospital mortality or admission to ICU, whichever came first. The key secondary end-point was in-hospital mortality. Results: Multivariable models were based on 1183 patients with complete data. Reduced food intake before and after hospital admission was found to have a negative prognostic impact for both the primary and secondary endpoint (P<0.001 for both). No association with BMI and WL was observed. Other predictors of outcomes were age and presence of multiple comorbidities. A significant interaction between obesity and multi-morbidity (2) was detected. Obesity was found to be a risk factor for composite end-point (HR¼1.36 [95%CI, 1.03-1.80]; P¼.031) and a protective factor against inhospital mortality (HR¼0.32 [95%CI, 0.20-0.51]; P<.001) in patients with and without multiple comorbidities, respectively. Secondary analysis (patients, N¼829), further adjusted for high C-reactive protein (>21 mg/dL) and LDH (>430 mU/mL) levels yielded consistent findings. Conclusion: Reduced food intake was strongly associated with negative clinical outcomes in non-critically ill, hospitalized COVID-19 patients. This simple and easily obtainable parameter may be useful to identify patients at highest risk of poor prognosis, who may benefit from prompt nutritional support. The presence of comorbidities could be the key factor, which may determine the protective or harmful role of a high body mass index in COVID-19. Disclosure of Interest: None declared. Rationale: This study aimed to characterise nutritional risk in COVID-19 inpatients, their outcomes based on nutritional risk status (inflammatory response, length of stay, ICU admission, inpatient mortality), and whether or not nutritional supplementation had any association with inpatient mortality.

Methods: This was a retrospective cohort study of adult inpatients admitted to University College London Hospital between February 2020 and July 2020 with PCR-confirmed SARS-CoV-2 (n¼518). Data were collected in a de-identified fashion from a paperless digital platform. 73.6% of patients (n¼381) had nutritional assessment on admission and were classified as low, moderate or high nutritional risk using the local Nutritional Scoring Tool (NST). Unpaired Student's T-tests were performed to compare statistical differences between mean values. Multivariate logistic regressions were performed to generate adjusted odds ratios accounting for co-morbidities (chronic lung disease, hypertension, diabetes, AKI/CKD, cancer, dementia), age>70, ICU admission and gender. Statistical significance was determined as p <.05. Results: 34.6% of patients (n¼132) were assessed as high nutritional risk, 23.4% (n¼89) were assessed as moderate nutritional risk and 42.0% (n¼160) were asessed as low nutritional risk on admission to hospital. Mean peak CRP of patients at moderate and high nutritional risk was 30 mg/L higher than those at low nutritional risk (p <.05, 95% CI 3 mg/L to 57 mg/L), and mean nadir albumin was 3g/L lower (p <.0001, 95% CI 2 g/L to 5 g/L). Inpatient length of stay was 5.8 days longer in patients at moderate and high nutritional risk compared to those at low nutritional risk (p <.001, 95% CI 2.4 to 9.2 days). Moderate nutritional risk on admission was an independent risk factor for ICU admission, adjusted OR 2.18 (95% CI 1.18 to 4.00), p <.05. High nutritional risk was an independent risk factor for mortality, adjusted OR 3.13 (95% CI 1.79 to 5.53), p <.0001. In patients at high nutritional risk, nutritional supplementation with oral nutritional supplements and/or nasogastric feeding was associated with lower odds of inpatient mortality, adjusted OR 0.26 (95% CI 0.09 e 0.69), p <.001. Overall, 64.8% of patients at high nutritional risk received nutritional supplementation. Conclusion: A large proportion of COVID-19 patients are at moderate or high nutritional risk on admission to hospital. This study showed they had a greater inflammatory response and longer length of stay compared to those at low nutritional risk. Patients at moderate nutritional risk had greater odds of requiring ICU admission, and patients at high nutritional risk had greater odds of inpatient mortality. Nutritional supplementation in the high nutritional risk group was associated with lower odds of inpatient mortality, yet only two-thirds received this simple intervention. More attention should be paid to nutritional assessment and supplementation in this high-prevalence, high-risk group of patients. Disclosure of Interest: None declared. Rationale: Critically ill COVID-19 patients seem hypermetabolic and difficult to feed enterally, due to high gastric residual volumes (GRV) and diarrhea. Our aim was to describe the association of nutritional intake and gastro-intestinal (GI) symptoms during first 14 days of ICU admission. Methods: Observational study including critically ill adult COVID-19 patients. Data on nutritional intake (enteral nutrition (EN) or parenteral nutrition) and GI symptoms were collected during 14 days after ICU admission. Energy and protein feeding goals were calculated conform ESPEN guidelines and actual intake was recorded. GI symptoms included GRV (ml/d), vomiting, abdominal distension and feces (ml/d). GI symptoms were defined as mild if at least one symptom occurred and as moderate when 2 symptoms occurred. Linear mixed model analysis was performed to explore the development of nutritional intake and GI symptoms over time at day (D) 0,4,10&14. Results: 150 patients were included (75% male; median age 64 years [54-70]). BMI upon admission was 28 kg/m 2 [25-33], of which 41% obese (BMI>30 kg/m 2 ). The majority received EN during admission (98% D4; 96% D10-14). Mean delivery of prescribed kcal increased from 87% at D4 to 93% D10-14. Protein goals expanded during admission (84% D4; 96% D10-14). Presence of moderate GI symptoms decreased (10% DO; 6% D4-10; 5% D14), reversively mild GI symptoms increased. None of patients developed severe GI failure. Development of high GRV fluctuated (5% D0; 23% D4; 14% D10; 8% D14) and diarrhea increased during admission (5% D0; 22% D4; 25% D10; 27% D14). Association between the amount of the prescribed kcal and GI symptoms (p<0.0001) attenuated over time. Conclusion: GI symptoms occurred frequently but were no major barrier for EN in COVID-19 patients, while nutritional intake were just below requirements during the first 14 days of ICU admission. Disclosure of Interest: None declared. Rationale: Insulin resistance and hyperinsulinemia play important roles in the progression of multiple chronic disease and conditions. Diet modulates insulin response; however, evidence is limited regarding whether diet with higher insulinemic potential is associated with all-cause and causespecific mortality risk. Methods: We prospectively followed 63,464 women from the Nurses' Health Study (1986-2016) and 42,883 men from the Health Professionals Follow-up Study . Diet was assessed by food frequency questionnaires every 4 years. The insulinemic potential of diet was evaluated using a food-based empirical dietary index for hyperinsulinemia (EDIH) that was pre-defined based on predicting circulating C-peptide concentrations. Results: During 2,815,428 person-years of follow-up, 38,322 deaths occurred. In the pooled multivariable-adjusted analyses, a higher dietary insulinemic potential, as indicated by higher EDIH scores, was associated with an increased risk of mortality from all causes (hazard ratio [ Additional adjustment for body mass index slightly attenuated the association between EDIH and CVD mortality (HR: 1.28; 95% CI: 1.19, 1.37; P-trend<0.001), suggesting adiposity may partly mediate the observed association. Moreover, compared with participants whose EDIH scores remained stable over an 8-year period, those with the greatest increases had a higher subsequent risk of all-cause (HR: 1.13; 95%CI: 1.09, 1.18; P-trend<0.001) and CVD (HR: 1.10; 95% CI: 1.00, 1.20; P-trend¼0.005) mortality. Conclusion: Higher insulinemic potential of the diet was associated with higher risk of all-cause and cause-specific mortality. Reducing the insulinemic potential of the diet may therefore be a means of improving overall health and preventing premature death. Disclosure of Interest: None declared. 

Methods: A multicentre, randomised, placebo-controlled, double-blind (the ECLISP) trial, was conducted to assess (1) the efficacy of consuming LcS in preventing AAD and CDI; (2) whether proton pump inhibitors (PPI) and undernutrition-risk are risk factors for AAD/CDI and (3) associated changes in quality of life. LcS or placebo was given once daily, within 48 hours from the start of antibiotic, for the duration of an antibiotic course and continued for 7 days thereafter. Follow up was set at 7 and 30 days after the antibiotic course finished

Conclusion: The present study indicates that LcS could not prevent AAD in unselected SCI patients but has the potential to prevent AAD in the higher risk group of patients on PPI. Confirmatory studies are needed to allow translation of this apparent therapeutic success into improved clinical outcomes